IFNAR2 Rabbit pAb for WB, IHC-P, IF/ICC, ELISA - P48551

Core Product Specifications and Parameters

Biological Background: IFNAR2 Function and Localization

• IFNAR2 (interferon alpha/beta receptor 2), also known as IFNABR, IFNARB, or IFN-alpha-REC, encodes the type I interferon receptor beta chain. Multiple isoforms are generated by alternative splicing; notably, isoform 3 is a secreted form detected in urine (PubMed:7759950, PubMed:8181059). The receptor is expressed in blood cells, lymphoblastoid and fibrosarcoma cell lines. Related references: PMID:7759950 PMID:8181059
• Together with IFNAR1, IFNAR2 forms the functional heterodimeric receptor for type I interferons (IFN-α, -β, -ε, -ω, -κ) (PubMed:10049744, PubMed:10556041, PubMed:21854986). Ligand engagement brings the subunits into close proximity, triggering activation of associated Janus kinases. Related references: PMID:10049744 PMID:10556041 PMID:21854986
• Receptor activation drives trans-phosphorylation of JAK1 (bound to IFNAR2) and TYK2 (bound to IFNAR1) (PubMed:10556041, PubMed:11682488, PubMed:12105218). Subsequently, specific tyrosine residues on the intracellular domains of IFNAR1/2 become phosphorylated, creating docking sites for STAT1 and STAT2 (PubMed:11682488, PubMed:12105218, PubMed:21854986). Related references: PMID:10556041 PMID:11682488 PMID:12105218 PMID:21854986
• Phosphorylated STAT proteins translocate to the nucleus to modulate transcription of hundreds of interferon-stimulated genes (ISGs), orchestrating antiviral, antiproliferative, and immunomodulatory responses (PubMed:12105218, PubMed:28165510, PubMed:9121453). Related references: PMID:12105218 PMID:28165510 PMID:9121453
• Apart from its role in signal transduction, IFNAR2 can also act as a potent inhibitor of type I interferon receptor activity, likely through competitive ligand binding or regulation of receptor stability.
• The protein spans the cell membrane and contains extracellular fibronectin type-III domains; it undergoes glycosylation and disulfide bond formation, as evidenced by proteomic analyses, and is subject to regulatory phosphorylation.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the extracellular domain (aa 27-243), thus the antibody is expected to target the ligand-binding region; suitable for receptor-blocking studies or detection of soluble receptors in biofluids.
• For Western blotting, a band at ~58 kDa is predicted; however, due to N-linked glycosylation and potential proteolytic processing, additional bands or a higher apparent molecular weight may be observed. Validate with positive (e.g., IFN-treated cells) and negative controls.
• In immunohistochemistry (IHC-P) and immunofluorescence (IF/ICC), membrane staining is anticipated. For tissues or cells expressing the secreted isoform, cytoplasmic or extracellular matrix signal may be detected; appropriate fixation and permeabilization protocols should be tested.
• For ELISA, this polyclonal antibody can be used as a detection reagent when paired with a suitable monoclonal capture antibody; cross-reactivity with mouse and rat IFNAR2 should be verified in the assay matrix.
• As a polyclonal antibody, lot-to-lot consistency should be monitored, and titration experiments are recommended for new applications.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a dedicated one-stop sourcing partner for IVD raw materials, offering diagnostic developers and researchers streamlined access to high-quality antibodies, antigens, and ancillary reagents. This IFNAR2 polyclonal antibody supports the development of assays targeting type I interferon pathways and innate immunity. Beyond individual reagents, CamelBio provides services such as customized antibody pair screening, bulk production, and procurement of challenging targets, ensuring consistency and traceability from concept to clinic.